Japan and China discuss clinical trials and ethnic factors
This article was originally published in Scrip
Executive Summary
The drug regulatory authorities of Japan and China are continuing to discuss issues related to participation in global clinical trials, information sharing and the influence of ethnic factors, as part of a broader collaboration between regulators in Northeast Asia.